Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TAK-147 (Takeda).

H Mucke1

  • 1HM Pharma Consultancy, Wien, Austria. h.mucke@hmpharmacon.com

Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

TAK-147, a CNS-specific acetylcholinesterase inhibitor, is being developed for Alzheimer's disease. This potential Alzheimer's treatment entered Phase III clinical trials in Japan by late 1999.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The central part of the cyanelle rDNA unit of Cyanophora paradoxa: Sequence comparison with chloroplasts and cyanobacteria.

Plant molecular biology·2013
Same author

Comparison of the cyanelle DNA from two different strains of Cyanophora paradoxa.

Current genetics·2013
Same author

The role of imatinib in the treatment of pulmonary hypertension.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

KA-672 Dr Wilmar Schwabe GmbH & Co.

IDrugs : the investigational drugs journal·2008
Same author

Clomethiazole (Astra Arcus AB).

IDrugs : the investigational drugs journal·2005
Same author

Brain '99/BrainPET '99 Cerebral Blood Flow and Metabolism symposium & quantification of brain function with PET conference. 13-17 June 1999, Copenhagen, Denmark.

IDrugs : the investigational drugs journal·2005
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Neuroscience and Pharmacology
  • Drug Development for Neurodegenerative Diseases

Background:

  • Alzheimer's disease (AD) poses a significant unmet medical need.
  • Acetylcholinesterase inhibitors represent a key therapeutic strategy for AD.
  • TAK-147 is a novel CNS-specific acetylcholinesterase inhibitor developed by Takeda.

Purpose of the Study:

  • To evaluate the efficacy and safety of TAK-147 as a potential treatment for Alzheimer's disease.
  • To advance TAK-147 through late-stage clinical development.

Main Methods:

  • Phase III clinical trials were initiated in Japan.
  • Pharmacological profiling focused on central nervous system (CNS) acetylcholinesterase inhibition.

Main Results:

Related Experiment Videos

  • TAK-147 progressed to Phase III clinical trials by November 1999.
  • Financial projections indicated a potential 2002 product launch with substantial peak sales.

    • Conclusions:

    • TAK-147 demonstrated potential as a therapeutic agent for Alzheimer's disease.
    • The drug's development trajectory suggested a promising future in the AD market.